Clinical Trials Logo

Malignancies clinical trials

View clinical trials related to Malignancies.

Filter by:

NCT ID: NCT01404728 Completed - Malignancies Clinical Trials

Longitudinal Evaluation Study of Vaginal Stenosis With and Without Pelvic Radiation Therapy

Start date: January 8, 2013
Phase: N/A
Study type: Observational

This study evaluates the effects of treatment with a vaginal dilator to reduce vaginal stenosis in women receiving pelvic radiation therapy for pelvic malignancies.

NCT ID: NCT00329329 Terminated - Malignancies Clinical Trials

Study of Satraplatin With Capecitabine to Treat Advanced Solid Malignancies

Start date: May 2006
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the maximally tolerated dose (MTD) and Phase 2 recommended dose of satraplatin when administered in combination with capecitabine in patients with advanced solid malignancies.

NCT ID: NCT00320827 Completed - Lymphoma Clinical Trials

Study of CS-1008 in Patients With Advanced Solid Malignancies and Lymphomas (Without Leukemic Component)

Start date: n/a
Phase: Phase 1
Study type: Interventional

This is a dose escalation study of CS-1008 (humanized anti-DR5 antibody) to determine the recommended Phase 2 dose and the maximum tolerated dose. Drug will be administered for six weeks and possibly up to 12 weeks depending on response.

NCT ID: NCT00316511 Completed - B-Cell Lymphoma Clinical Trials

Study of L-NDDP (Aroplatin) in Patients With Advanced Solid Malignancies or B-Cell Lymphoma

Start date: March 2006
Phase: Phase 1
Study type: Interventional

This is a dose escalation study. Patients will be enrolled in cohorts of three patients each, and escalation of dose to the next cohort will be determined based on dose-limiting toxicity (DLT) in the previous cohort. This study aims to identify the maximum tolerated dose (MTD) of intravenous L-NDDP. Once the MTD has been determined, an additional four patients will be enrolled at that dose level. While the MTD is determined based on safety data from each cohort's first cycle of L-NDDP therapy only, patients may continue treatment with additional cycles of L-NDDP at the same dose as their starting dose until documented progression, unacceptable toxicity, or another off study criterion is met. Patients who have not met any of the off study criteria and continue to receive L-NDDP therapy at the time when MTD is determined may be allowed to change L-NDDP dose to the MTD dose level. The study will also determine the pharmacokinetic profile of L-NDDP administration. Clinical activity of L-NDDP in solid tumor patients will be assessed as tumor response using the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Clinical activity of L-NDDP in B-cell lymphoma patients will be assessed using the International Working Group recommendations.